To determine if the CYP2C19 downregulation could be better explained by something other than NAFLD, we conducted single linear regressions of CYP2C19 mRNA abundance with each possible independent variable in our clinical and demographic data (Supplementary Data 12). The gene discussed is CYP2C19; the disease is metabolic dysfunction-associated steatotic liver disease.